Atria Wealth Solutions Inc. acquired a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,621 shares of the medical research company's stock, valued at approximately $316,000.
Several other hedge funds and other institutional investors also recently modified their holdings of EXAS. Huntington National Bank boosted its holdings in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after purchasing an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of Exact Sciences during the 3rd quarter valued at about $34,000. Capital Performance Advisors LLP purchased a new position in shares of Exact Sciences during the 3rd quarter worth approximately $35,000. Asset Planning Inc bought a new position in Exact Sciences in the fourth quarter worth $40,000. Finally, Modus Advisors LLC bought a new position in shares of Exact Sciences in the 4th quarter worth about $43,000. Hedge funds and other institutional investors own 88.82% of the company's stock.
Exact Sciences Trading Up 2.3 %
NASDAQ EXAS traded up $1.08 during trading on Tuesday, hitting $48.63. The stock had a trading volume of 1,475,994 shares, compared to its average volume of 2,312,795. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $9.03 billion, a PE ratio of -8.75 and a beta of 1.24. The firm has a 50 day moving average price of $53.71 and a 200 day moving average price of $59.67. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, equities research analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts have issued reports on the stock. Stifel Nicolaus decreased their target price on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Barclays cut their target price on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. TD Cowen increased their price target on Exact Sciences from $82.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Citigroup cut their price target on Exact Sciences from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. Finally, Benchmark reiterated a "buy" rating and set a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $71.94.
Check Out Our Latest Stock Report on Exact Sciences
Exact Sciences Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
